Skip to main content

Table 1 Phenotypic heterogeneity in a cohort of 282 cases of psoriatic arthritis

From: Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype

Age 55 ± 12
Male gender 134 (47)
Family history of psoriasis (n = 280) 175 (63)
Family history of PsA (n = 280) 45 (16)
Age of onset of psoriasis 28 ± 14
Psoriasis duration (years) 27 ± 14
Age of onset of PsA 35 ± 13
PsA duration (years) 19 ± 9
Years between psoriasis and PsA 6 (0 to 14)
Psoriasis before PsA 184 (65)
PsA before psoriasis 45 (16)
Psoriasis and PsA at same time 52 (18)
Nail disease 244 (79)
 Pitting 96 (34)
 Onycholysis 155 (55)
Peripheral arthritis 280 (99)
 Polyarthritis 258 (91)
 Oligoarthritis 21 (8)
Deformed joint count, if deformity 6 (4 to 12)
Enthesitisa 97 (34)
Dactylitisa 150 (53)
Sacroiliitisa 71 (25)
 Asymmetrica 51 (18)
 Symmetrica 18 (6)
Joint deformitya 183 (65)
Joint fusiona 83 (29)
Erosionsa (n = 281) 123 (44)
Osteolysisa (n = 281) 41 (15)
Current PASI 1.2 (0.3 to 2.8)
Max PASI 3.8 (1.8 to 9.2)
Plaque psoriasis only 224 (79)
Psoriasis, nonplaque 59 (21)
Uveitis 9 (3)
Total on TNFi 176 (62)
 Psoriasis requiring TNFi 32 (11)
 PsA requiring TNFi 171 (60)
Number of TNFi, if on TNFi 1 (1 to 2; range 1 to 4)
Number of DMARDs 1 (1 to 2; range 0 to 5)
  1. Data presented as mean ± standard deviation or n (%). DMARD, disease-modifying antirheumatic drug; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor. aVariables used to construct the propensity score.